PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies
Cancer Immunology, Immunotherapy · 2023-12 · 72 (12) · 3875-3893
DOI: 10.1007/s00262-023-03520-5 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Immunology, Immunotherapy, online erschienen am 13.10.2023. Verfasst von Ke Xin Lin und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, University of Western Ontario, London, ON, N6A 5A5, Canada. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 160-mal zitiert (Crossref) und nennt 166 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Canadian Institute of Health Research, The Natural Science and Engineering Research of Canada.
Abstract (Originalsprache)
Colorectal cancer (CRC) is the second most common cause of cancer mortality, with mismatch repair proficient (pMMR) and/or microsatellite stable (MSS) CRC making up more than 80% of metastatic CRC. Programmed death-ligand 1 (PD-L1) and programmed death 1 (PD-1) immune checkpoint inhibitors (ICIs) are approved as monotherapy in many cancers including a subset of advanced or metastatic colorectal cancer (CRC) with deficiency in mismatch repair (dMMR) and/or high microsatellite instability (MSI-H). However, proficient mismatch repair and microsatellite stable (pMMR/MSS) cold CRCs have not shown clinical response to ICIs alone. To potentiate the anti-tumor response of PD-L1/PD-1 inhibitors in patients with MSS cold cancer, combination strategies currently being investigated include dual ICI, and PD-L1/PD-1 inhibitors in combination with chemotherapy, radiotherapy, vascular endothelial growth factor (VEGF) /VEGF receptor (VEGFR) inhibitors, mitogen-activated protein kinase (MEK) inhibitors, and signal transducer and activation of transcription 3 (STAT3) inhibitors. This paper will review the mechanisms of PD-1/PD-L1 ICI resistance in pMMR/MSS CRC and potential combination strategies to overcome this resistance, summarize the published clinical experience with different combination therapies, and make recommendations for future avenues of research.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, University of Western Ontario, London, ON, N6A 5A5, Canada.
- Department of Physiology and Pharmacology, University of Western Ontario, London, Canada.
- Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
- Division of Surgical Oncology, Medical College of Wisconsin, Milwaukee, WI, USA.
- Department of Surgery, University of Western Ontario, London, ON, N6A 5A5, Canada.
- Department of Pathology, University of Western Ontario, London, ON, N6A 5A5, Canada. xzheng26@uwo.ca.
Förderung
- The Canadian Institute of Health Research
- The Natural Science and Engineering Research of Canada
Zitieren
APA
Lin, K. X., Istl, A. C., Quan, D., Skaro, A., Tang, E., & Zheng, X. (2023). PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunology, Immunotherapy, 72(12), 3875-3893. https://doi.org/10.1007/s00262-023-03520-5
Vancouver
Lin KX, Istl AC, Quan D, Skaro A, Tang E, Zheng X. PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies. Cancer Immunology, Immunotherapy. 2023;72(12):3875-3893. doi:10.1007/s00262-023-03520-5
BibTeX
@article{Lin2023,
author = {Lin, Ke Xin and Istl, Alexandra C and Quan, Douglas and Skaro, Anton and Tang, Ephraim and Zheng, Xiufen},
title = {PD-1 and PD-L1 inhibitors in cold colorectal cancer: challenges and strategies},
journal = {Cancer Immunology, Immunotherapy},
year = {2023},
volume = {72},
number = {12},
pages = {3875--3893},
doi = {10.1007/s00262-023-03520-5}
}
EUVIMED